https://www.selleckchem.com/pr....oducts/belvarafenib.
To quantify the survival impact of prolongation of definitive radiotherapy (RT) for head and neck cancer in a national, modern cohort, and to identify predictive factors for prolongation. The National Cancer Database was queried for adults with non-metastatic cancer of the nasopharynx, oropharynx, larynx, or hypopharynx diagnosed 2004-2015, treated with definitive RT to 66-70Gy in 30-35 fractions at 2-2.2Gy per fraction. Multivariable Cox regression and propensity score matching were used to model the survival impact of RT prolonga
Like
Comment
Share
